Navigation Links
Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
Date:10/28/2008

blinded study that compared the efficacy and safety of sugammadex versus neostigmine/glycopyrrolate in the reversal of profound rocuronium-induced neuromuscular blockade. Traditionally, reversal of nondepolarizing neuromuscular blocking agents (NMBAs) such as rocuronium or vecuronium has been achieved by using acetylcholinesterase inhibitors, such as neostigmine. However, these older agents cannot rapidly reverse profound neuromuscular blockade.

Neuromuscular blockade plays several critical roles in general anesthesia. Anesthesiologists use muscle relaxation to improve surgical conditions and to facilitate intubation and mechanical ventilation. Reversal agents reverse the effects of muscle relaxants, enabling patients to regain normal muscle function sooner and breathe on their own again.

Studies have shown that in clinical practice, patients are often extubated before complete recovery has occurred, leaving the patients at risk of associated postoperative complications such as airway obstruction or pulmonary complications. Residual neuromuscular blockade, which is an important cause of NMBA-associated morbidity in surgical patients, was not reported in any patient in this study.

"These results demonstrate the efficacy of sugammadex in rapidly reversing profound rocuronium-induced neuromuscular blockade, an option that is not possible with conventional reversal agents," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "This study shows that sugammadex offers advantages over neostigmine and may help improve anesthesia management in the millions of surgeries where muscle relaxation agents are used."

Key Findings

In the Signal study, sugammadex or neostigmine was administered at reappearance of 1-2 post-tetanic counts (profound neuromuscular blockade). The primary efficacy endpoint of the study was time from sugammadex or neostigmine/glycopyrrolate administration to
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. New Study Highlights Need for Better Interaction and Education Between Rheumatoid Arthritis Patients and Care Providers
2. QLT announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System
3. Psychological study reveals that red enhances mens attraction to women
4. Study reveals factors of exceptional health in old age
5. Eating whole grains lowers heart failure risk, according to new study
6. Bloomberg School of Public Health to lead nationwide aging study
7. Latest Pistachio Study Reveals Significant Reduction in Markers of Inflammation - an Emerging Risk Factor in Heart Disease
8. University of Illinois - Chicago Study: Raisins Contain Compounds that May Inhibit Cavity-causing Bacteria
9. Study Reveals Factors of Exceptional Health in Old Age
10. AUDIO from Medialink and Genzyme: Study in New England Journal of Medicine Shows Investigational Compound Reduced Relapses and Disability in Patients With MS
11. Study finds that practice makes perfect in lung cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Humans damaging the oceans 9411 1Humans damaging the oceans 9411 2Humans damaging the oceans 9411 3Bizarre walking bat has ancient heritage 9408 1Bizarre walking bat has ancient heritage 9408 2Organic food not nutritionally better than conventionally produced food 9405 1Organic food not nutritionally better than conventionally produced food 9405 2